BioPharmSignal logoBioPharmSignal

Biotech News

MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products

MiMedx (MDXG)MiMedxFinancing

Agreement expands offering to include additional sheet, particulate and flowable products MARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Summit Products Group (“Summit”)

Related news

APGEApogee Therapeutics2026-03-26 20:01 EST

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

MDXGMiMedx2026-03-05 13:00 EST

MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields

APGEApogee Therapeutics2025-10-10 20:01 EST

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

ALVOAlvotech2026-06-18 09:51 EST

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

STTKShattuck Labs2026-06-10 04:21 EST

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

STTKShattuck Labs2026-06-09 20:18 EST

Shattuck Labs, Inc. Announces Proposed Public Offering

MDXGMiMedx2026-04-02 13:15 EST

MIMEDX to Sponsor Leading Advanced Wound Care Conferences

CHRSCoherus BioSciences, Inc.2026-02-17 21:11 EST

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

CHRSCoherus BioSciences, Inc.2026-02-13 02:18 EST

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

ENTXEntera Bio2026-07-27 12:30 EST

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

View all latest news

MiMedx

Placental Tissue Products MIMEDX develops and commercializes placental-tissue products for wound care, burns and surgery. Its processing and product portfolio are designed to provide extracellular-matrix and biologic materials that support healing and tissue repair. Wound-Care Portfolio The company has more than a decade of experience...

Recent company news

MDXGMiMedx2026-07-29 20:07 EST

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

MDXGMiMedx2026-07-29 20:01 EST

MIMEDX to Acquire Sanara MedTech

MDXGMiMedx2026-07-20 12:00 EST

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MDXGMiMedx2026-05-21 12:45 EST

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

MDXGMiMedx2026-05-08 12:00 EST

MIMEDX Announces Launch of G4Derm® Plus

Stock data

Close
4.18 USD
Market cap
531.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States